LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2016-06, Vol.27, p.ii140 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | ii140 |
| container_title | Annals of oncology |
| container_volume | 27 |
| creator | Bruix, J. Merle, P. Granito, A. Huang, Y.-H. Bodoky, G. Yokosuka, O. Rosmorduc, O. Breder, V. Gerolami, R. Masi, G. Ross Paul, J. Qin, S. Song, T. Bronowicki, J.-P. Ollivier-Hourmand, I. Kudo, M. LeBerre, M.-A. Baumhauer, A. Meinhardt, G. Han, G. |
| description | |
| doi_str_mv | 10.1093/annonc/mdw237.03 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdw237_03</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdw237_03</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1303-dd06d71cb0852cd12db37eb2a2bd9d1bfdf09234d4c74a7919c57d43498401513</originalsourceid><addsrcrecordid>eNo1kDtPwzAYRTOARHnsjN8IEmntOGlqthIFilSpUoE5cvxojFw7slOq8u_4Z7gqTFd3OffqJMktRmOMKJkwa53lk63YZ6QcI3KWjBDNSFoWJL9ILkP4RAhNaUZHyc_yaZ4iArVSmjN-AGYFBKbkcACnwMuN87FZ3cKX9GEXoDeMy9aBttCzQUs7BNjroYNOxu64NGZnmAfOPNfWbRncLarqHnrvNl6GoO0GnIXwz32MI2FnIiXuDZ2M4EF6G9HOMvMAPj5yW_0tBfQdCxIIrOu31bqqYfCamevkXDET5M1fXiUfz_V7tUiXq5fXar5MOSaIpEKgqSgxb9GsyLjAmWhJKduMZa2gArdKqKOjXOS8zFlJMeVFKXKS01mOcIHJVYJOXO5dCF6qpvd6y_yhwag5am9O2puT9gYR8gs9RX3l</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Bruix, J. ; Merle, P. ; Granito, A. ; Huang, Y.-H. ; Bodoky, G. ; Yokosuka, O. ; Rosmorduc, O. ; Breder, V. ; Gerolami, R. ; Masi, G. ; Ross Paul, J. ; Qin, S. ; Song, T. ; Bronowicki, J.-P. ; Ollivier-Hourmand, I. ; Kudo, M. ; LeBerre, M.-A. ; Baumhauer, A. ; Meinhardt, G. ; Han, G.</creator><creatorcontrib>Bruix, J. ; Merle, P. ; Granito, A. ; Huang, Y.-H. ; Bodoky, G. ; Yokosuka, O. ; Rosmorduc, O. ; Breder, V. ; Gerolami, R. ; Masi, G. ; Ross Paul, J. ; Qin, S. ; Song, T. ; Bronowicki, J.-P. ; Ollivier-Hourmand, I. ; Kudo, M. ; LeBerre, M.-A. ; Baumhauer, A. ; Meinhardt, G. ; Han, G.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>DOI: 10.1093/annonc/mdw237.03</identifier><language>eng</language><ispartof>Annals of oncology, 2016-06, Vol.27, p.ii140</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1303-dd06d71cb0852cd12db37eb2a2bd9d1bfdf09234d4c74a7919c57d43498401513</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Bruix, J.</creatorcontrib><creatorcontrib>Merle, P.</creatorcontrib><creatorcontrib>Granito, A.</creatorcontrib><creatorcontrib>Huang, Y.-H.</creatorcontrib><creatorcontrib>Bodoky, G.</creatorcontrib><creatorcontrib>Yokosuka, O.</creatorcontrib><creatorcontrib>Rosmorduc, O.</creatorcontrib><creatorcontrib>Breder, V.</creatorcontrib><creatorcontrib>Gerolami, R.</creatorcontrib><creatorcontrib>Masi, G.</creatorcontrib><creatorcontrib>Ross Paul, J.</creatorcontrib><creatorcontrib>Qin, S.</creatorcontrib><creatorcontrib>Song, T.</creatorcontrib><creatorcontrib>Bronowicki, J.-P.</creatorcontrib><creatorcontrib>Ollivier-Hourmand, I.</creatorcontrib><creatorcontrib>Kudo, M.</creatorcontrib><creatorcontrib>LeBerre, M.-A.</creatorcontrib><creatorcontrib>Baumhauer, A.</creatorcontrib><creatorcontrib>Meinhardt, G.</creatorcontrib><creatorcontrib>Han, G.</creatorcontrib><title>LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial</title><title>Annals of oncology</title><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo1kDtPwzAYRTOARHnsjN8IEmntOGlqthIFilSpUoE5cvxojFw7slOq8u_4Z7gqTFd3OffqJMktRmOMKJkwa53lk63YZ6QcI3KWjBDNSFoWJL9ILkP4RAhNaUZHyc_yaZ4iArVSmjN-AGYFBKbkcACnwMuN87FZ3cKX9GEXoDeMy9aBttCzQUs7BNjroYNOxu64NGZnmAfOPNfWbRncLarqHnrvNl6GoO0GnIXwz32MI2FnIiXuDZ2M4EF6G9HOMvMAPj5yW_0tBfQdCxIIrOu31bqqYfCamevkXDET5M1fXiUfz_V7tUiXq5fXar5MOSaIpEKgqSgxb9GsyLjAmWhJKduMZa2gArdKqKOjXOS8zFlJMeVFKXKS01mOcIHJVYJOXO5dCF6qpvd6y_yhwag5am9O2puT9gYR8gs9RX3l</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Bruix, J.</creator><creator>Merle, P.</creator><creator>Granito, A.</creator><creator>Huang, Y.-H.</creator><creator>Bodoky, G.</creator><creator>Yokosuka, O.</creator><creator>Rosmorduc, O.</creator><creator>Breder, V.</creator><creator>Gerolami, R.</creator><creator>Masi, G.</creator><creator>Ross Paul, J.</creator><creator>Qin, S.</creator><creator>Song, T.</creator><creator>Bronowicki, J.-P.</creator><creator>Ollivier-Hourmand, I.</creator><creator>Kudo, M.</creator><creator>LeBerre, M.-A.</creator><creator>Baumhauer, A.</creator><creator>Meinhardt, G.</creator><creator>Han, G.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201606</creationdate><title>LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial</title><author>Bruix, J. ; Merle, P. ; Granito, A. ; Huang, Y.-H. ; Bodoky, G. ; Yokosuka, O. ; Rosmorduc, O. ; Breder, V. ; Gerolami, R. ; Masi, G. ; Ross Paul, J. ; Qin, S. ; Song, T. ; Bronowicki, J.-P. ; Ollivier-Hourmand, I. ; Kudo, M. ; LeBerre, M.-A. ; Baumhauer, A. ; Meinhardt, G. ; Han, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1303-dd06d71cb0852cd12db37eb2a2bd9d1bfdf09234d4c74a7919c57d43498401513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bruix, J.</creatorcontrib><creatorcontrib>Merle, P.</creatorcontrib><creatorcontrib>Granito, A.</creatorcontrib><creatorcontrib>Huang, Y.-H.</creatorcontrib><creatorcontrib>Bodoky, G.</creatorcontrib><creatorcontrib>Yokosuka, O.</creatorcontrib><creatorcontrib>Rosmorduc, O.</creatorcontrib><creatorcontrib>Breder, V.</creatorcontrib><creatorcontrib>Gerolami, R.</creatorcontrib><creatorcontrib>Masi, G.</creatorcontrib><creatorcontrib>Ross Paul, J.</creatorcontrib><creatorcontrib>Qin, S.</creatorcontrib><creatorcontrib>Song, T.</creatorcontrib><creatorcontrib>Bronowicki, J.-P.</creatorcontrib><creatorcontrib>Ollivier-Hourmand, I.</creatorcontrib><creatorcontrib>Kudo, M.</creatorcontrib><creatorcontrib>LeBerre, M.-A.</creatorcontrib><creatorcontrib>Baumhauer, A.</creatorcontrib><creatorcontrib>Meinhardt, G.</creatorcontrib><creatorcontrib>Han, G.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bruix, J.</au><au>Merle, P.</au><au>Granito, A.</au><au>Huang, Y.-H.</au><au>Bodoky, G.</au><au>Yokosuka, O.</au><au>Rosmorduc, O.</au><au>Breder, V.</au><au>Gerolami, R.</au><au>Masi, G.</au><au>Ross Paul, J.</au><au>Qin, S.</au><au>Song, T.</au><au>Bronowicki, J.-P.</au><au>Ollivier-Hourmand, I.</au><au>Kudo, M.</au><au>LeBerre, M.-A.</au><au>Baumhauer, A.</au><au>Meinhardt, G.</au><au>Han, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial</atitle><jtitle>Annals of oncology</jtitle><date>2016-06</date><risdate>2016</risdate><volume>27</volume><spage>ii140</spage><pages>ii140-</pages><issn>0923-7534</issn><doi>10.1093/annonc/mdw237.03</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2016-06, Vol.27, p.ii140 |
| issn | 0923-7534 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdw237_03 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| title | LBA-03 Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T10%3A22%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LBA-03%20Efficacy%20and%20safety%20of%20regorafenib%20versus%20placebo%20in%20patients%20with%20hepatocellular%20carcinoma%20(HCC)%20progressing%20on%20sorafenib:%20results%20of%20the%20international,%20randomized%20phase%203%20RESORCE%20trial&rft.jtitle=Annals%20of%20oncology&rft.au=Bruix,%20J.&rft.date=2016-06&rft.volume=27&rft.spage=ii140&rft.pages=ii140-&rft.issn=0923-7534&rft_id=info:doi/10.1093/annonc/mdw237.03&rft_dat=%3Ccrossref%3E10_1093_annonc_mdw237_03%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |